Cryopreserved PBMC were thawed, washed, resuspended in RPMI + 10% FBS (R10), and rested for 3 hours at 37°C. Following the 3-hour rest interval, the appropriate number of cells were transferred to a 48-well plate and incubated for 2 hrs with our panel of 10 LRA. Following this 2-hour incubation period,
GolgiPlug (BD, cat. no. 555029) and
GolgiStop (BD, cat. no. 554724) were added to each condition at a concentration of 1:1000 and 6:10000 respectively, then incubated at 37°C for an additional 16 hrs. Cells were harvested, pelleted, resuspended, stained for 20 minutes at 4°C with surface staining mAb (CD3-BV605, CD4-BV421, CD8-PerCp-Cy5.5 and LIVE/DEAD Near-IR stain), fixed and permeabilized as described above, and then stained for 30 minutes at 4°C with the intracellular mAb
TNF-α- PE/Dazzle-594 (Biolegend cat. no. 502946),
IL-2- PE/Cy7 (BD cat. no. 560707) and
IFN-γ- BV510 (Biolegend cat. no. 502544). PBMC were washed and fixed in (
BD cytofix fixation buffer, cat. no. 554655) prior to flow cytometry analysis, as described above.
Lilie T., Bouzy J., Asundi A., Taylor J., Roche S., Olson A., Coxen K., Corry H., Jordan H., Clayton K., Lin N, & Tsibris A. (2023). Opioid use does not limit potent low-dose HIV-1 latency reversal agent boosting. medRxiv.